Loading asset research
Q2 2026 earnings · After close · Sep 21
Abivax SA American Depositary Shares
ABVXNasdaq · USD · StocksQuote as of · Exchange session not verified$118.79
+2.45%
Today
ABVX
Loading 1D prices…
Market cap
$10.4B
Volume
893.5K
52w high
$148.8352w low
$69.81Company profile
Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Paris, United States
Employees
80
Fiscal year end
1231
CIK
1956827
Session & valuation
Open$115.46
Previous close$115.95
Day high$119.02
Day low$114.68
30-day avg. volume908.7K
Outstanding shares78.5M
Diluted EPS-$4.83
Latest annual period
P/E (trailing)-24.59
P/E (forward)-35.50
Price / book18.83
Beta-0.25
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CYTKCytokinetics Incorporated Common Stock | $10.3B | $88M | -891.60% | -$6.54 | +0.19% | Buy |
| RDYDr. Reddy's Laboratories Ltd Common Stock | $9.9B | — | — | $51.42 | +1.54% | Sell |
| PTGXProtagonist Therapeutics Inc. Common Stock | $9.6B | $46M | -282.83% | -$2.05 | +2.08% | Buy |
| PRAXPraxis Precision Medicines Inc. Common Stock | $9.3B | $0.00 | — | -$13.48 | +0.13% | Buy |
| AXSMAxsome Therapeutics Inc. Common Stock | $11.6B | $638.5M | -28.69% | -$3.68 | +4.61% | Buy |